本帖最后由 老马 于 2012-1-13 21:20 编辑 ) w; n* B; z& f4 A9 I- l
2 ]+ M* A+ z2 q# w- L- O; o- U- }
爱必妥和阿瓦斯丁的比较9 r( O2 ? ^/ a M E
6 e* q7 q% l0 K; chttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/6 H, u" X: \% J
: ? K5 L, ~9 y" D& ~; s
2 K0 @, a# Y# @9 \+ ihttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
4 a$ \6 R5 ?0 H7 `4 F/ c1 L==================================================
4 ?# v" C! Y7 O4 yOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
, k$ d2 `) M4 k% G9 t U% y, NPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point." z, ^& R ^! s. Q" d% D' K/ C
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
0 f9 M. B# P6 |, Y& _
|